Giant cell arteritis

Harrow Completes Transfer of the TRIESENCE® New Drug Application

Retrieved on: 
Wednesday, November 29, 2023
Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Optical, Biotechnology, NDA, Marketing, New Drug Application, Uveitis, Vitrectomy, Giant cell arteritis, Acquisition, Pharmaceutical industry

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy.

Key Points: 
  • Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy.
  • In January of 2023, Harrow agreed to acquire the U.S. commercial rights to TRIESENCE.
  • Aside from the transfer of the TRIESENCE NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.
  • We remain excited to be able to provide TRIESENCE to the U.S. ophthalmic community soon.”

Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

Retrieved on: 
Wednesday, October 4, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Odyssey, Abstract, GSK, Bachelor of Science in Human Biology, University, Boston University Chobanian & Avedisian School of Medicine, Emergency medicine, Biochemistry, Internal medicine, Upadacitinib, Lead, Multimedia, Rheumatology, Rheumatoid arthritis, Boston University School of Public Health, Stanford University School of Medicine, Medical research, Vaccine, Division, AbbVie, VA Palo Alto Health Care System, Faculty, Immunology, Pharmacology, Therapy, Boston Medical Center, Giant cell arteritis, Stanford University Medical Center, Inflammation, Pharmaceutical industry, Nursing, Science

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.
  • In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets.
  • View the full release here: https://www.businesswire.com/news/home/20231004996667/en/
    Jeremy Sokolove, M.D., Chief Medical Officer of Odyssey Therapeutics, Inc. (Photo: Business Wire)
    “As the newest member of our executive leadership team, Dr. Sokolove’s medical expertise and background in the biopharmaceutical industry will be critical to the success of our clinical development programs and achieving our corporate goals,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
  • “It’s an exciting time to join Odyssey as the organization transitions to a clinical-stage biotechnology company,” said Dr. Sokolove.

Global Healthy Living Foundation Receives Four-Year CDC Grant to Elevate Polymyalgia Rheumatica Awareness and Education

Retrieved on: 
Wednesday, September 20, 2023
Communications, Telemedicine, Virtual Medicine, Philanthropy, Other Health, Other Education, Social Media, General Health, Health, Foundation, Education, Cleveland Clinic, PMR, Fever, GCA, Quality of life, Medicine, Artery, Research, Inflammation, Biomarker, Neck, Rheumatoid arthritis, DO, Patient, Frustration, Giant cell arteritis, Fatigue, Disease, Dietary supplement

GHLF's work will analyze PMR data, assess awareness among health professionals, and convene expert panels to improve diagnostic tools.

Key Points: 
  • GHLF's work will analyze PMR data, assess awareness among health professionals, and convene expert panels to improve diagnostic tools.
  • The goal is to bolster the understanding of PMR among patients, medical professionals, and the public.
  • We can only enhance the quality of life for those who get diagnosed in the first place.
  • For more insights about the Global Healthy Living Foundation and its ongoing initiatives, please visit https://www.ghlf.org .

The Canadian Dermatology Association Announces 2023 Award Recipients

Retrieved on: 
Monday, June 19, 2023
Smoke, Hair, Dermatitis, The Ottawa Hospital, CHEO, Atopic dermatitis, University of Ottawa Heart Institute, Doctor of Philosophy, Joint, CDA, Retirement, Patient, Member, Pain management, Health, Clinical, Giant cell arteritis, Disease, University, Diet, Physician, Teaching, Skin cancer, Research, University of Pretoria Faculty of Veterinary Science, HS, Work, Knowledge, ESC, Smoking, Skin, Royal college, OSCE, Tobacco, Hidradenitis suppurativa, COVID-19, Nail, Rheumatology, Medicine, Publication, Journal of Cutaneous Medicine and Surgery, Inflammation, Anzac of the Year Award, Education, Suggestion, University of Saskatchewan, Consultant, Light, Student, Pharmacist, Dalhousie University, Nursing, Medical device, Dermatology, DRIVE

OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is excited to announce this year’s recipients of its Member Awards and Public Education Awards.

Key Points: 
  • OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is excited to announce this year’s recipients of its Member Awards and Public Education Awards.
  • This award honours certified dermatologists who have made a lasting impact in dermatology through their professional accomplishments.
  • Dr. Peter Hull’s longstanding commitment to excellence in dermatology began in 1978 when he completed his dermatology training at the University of Pretoria.
  • The CDA Resident Writing Award recognizes dermatology residents who contribute and share their expertise and experiences within the dermatology community and have contributed significant knowledge in the dermatology field through publications.

Shields Health Solutions Awards Resident Research Grant

Retrieved on: 
Thursday, October 20, 2022
Health, Practice Management, Managed Care, General Health, Research, Science, Pharmaceutical, LinkedIn, Doctor of Pharmacy, Dyslipidemia, Cardiovascular disease, Risk, Rheumatoid arthritis, Autoimmune disease, MCI Inc., YouTube, Juvenile idiopathic arthritis, Lipid, Patient, Hospital, Research, Psoriatic arthritis, Â, Partnership, Technology, University, Shield, Atopic dermatitis, Incidence, Social media, Blog, Ulcerative colitis, Giant cell arteritis, Pharmacist, Solution, Pharmaceutical industry, Health insurance, Pharmacy, Facebook

Shields Health Solutions (Shields), the nations premier specialty pharmacy accelerator, is proud to award a resident research grant in the amount of $5,000 to supplement existing projects or initiatives which advance health system specialty pharmacy in Q4 of 2022.

Key Points: 
  • Shields Health Solutions (Shields), the nations premier specialty pharmacy accelerator, is proud to award a resident research grant in the amount of $5,000 to supplement existing projects or initiatives which advance health system specialty pharmacy in Q4 of 2022.
  • Our research grant program is central to our mission to improve health system specialty pharmacies through innovation, said Brian Smith, Chief Pharmacy Officer at Shields.
  • With the support of the resident research grant from Shields Health Solutions, we can compile data on dyslipidemia management and create a recommended protocol.
  • To learn more about Shields, visit https://www.shieldshealthsolutions.com/
    Shields Health Solutions (Shields) is the premier specialty pharmacy accelerator in the country.

Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica

Retrieved on: 
Friday, September 9, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cardiovascular disease, Osteocalcin, Insulin resistance, Osteoporosis, Patient, PMR, Polymyalgia rheumatica, Steroid, Dyslipidemia, Autoimmune disease, Vasculitis, Autoimmunity, Doctor of Philosophy, Toxicity, Rheumatology, Disease, Giant cell arteritis, Medication, C-reactive protein, Tissue, Pains, NCT, Glaucoma, Bruise, Endocrinology, Glucocorticoid, Skin, ACHES, Weight gain, Tissue (biology), Cortisone, Stroke, Hypertension, Aortic aneurysm, Bone loss, GCA, Myalgia, Risk, Motion, Diabetes, Insomnia, Muscle atrophy, Life, Degenerative disease, Prednisolone, Pharmaceutical industry, Dietary supplement

This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.

Key Points: 
  • This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.
  • If we observe separation of the desired from undesired effects of prednisolone, well be an important step closer to solving a decades-old puzzle in autoimmune disease treatment.
  • Patients with PMR taking a daily 10mg oral dose of prednisolone may be eligible for the trial.
  • To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .

Vasculitis Pipeline Insights Report 2022: Comprehensive Insights about 40+ Companies and 40+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, Giant, Amputation, NDA, GCA, News, C5a, Giant cell arteritis, Clinical trial, Axial spondyloarthritis, Antidepressant discontinuation syndrome, ANCA, B-cell activating factor, Research, Psoriasis, Giant cell, Novartis, Route of administration, E-selectin, Route, Inflammation, Time-invariant system, III, Psoriatic arthritis, Inactive, AAV, Technology, Discovery, Secukinumab, Blood, ROA, Belimumab, Administration, Acquisition, Vascular disease, Regeneration, Survival, Medical device, Pharmaceutical industry, Vaccine, Vasculitis

The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.

Key Points: 
  • The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.
  • The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D.
  • Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

The Relapsing Polychondritis Foundation Invests in the Next Phase of VEXAS Research

Retrieved on: 
Thursday, March 31, 2022
Disease, Giant cell arteritis, Race, Trachea, Febrile neutrophilic dermatosis, NYU Langone Health, Hematology, Letter, VEXAS syndrome, Classification, Catholic University of Leuven (1834–1968), Internal medicine, Degenerative disease, Genomics, Lists of diseases, Diagnosis, Fever of unknown origin, NEW, Polyarteritis nodosa, Mortality, Cartilage, Inflammation, Nose, Research, Aorta, Episcleritis, RP, Hypoesthesia, Joint, Autoimmune disease, Vacuole, Anemia, UBA1, NIH, Society, Sex linkage, Physician, Science, Genetics, Awareness, Fatigue, Rash, Division, Patient, American Society of Hematology, Pharmaceutical industry, Medical device, Medicine, Animal, VEXAS, Lupus, Rheumatology

NEW YORK, March 31, 2022 /PRNewswire-PRWeb/ --VEXAS is an acronym for: Vacuoles, E1 ubiquitin Activating Enzyme, X-linked, Autoinflammatory, Somatic, with each letter representing one of the hallmark features of this novel autoinflammatory syndrome¹,². The discovery of VEXAS syndrome is revolutionary because it demonstrated that autoimmune disorders previously thought to be unrelated to each other, like relapsing polychondritis (RP), polyarteritis nodosa, Sweet syndrome, and giant cell arteritis, share a common acquired, somatic mutation in the UBA1 gene². UBA1 gene mutations result in the decreased production of an enzyme that breaks-down misfolded proteins and are clinically associated with systemic inflammation, anemia, and bone marrow dysplasia.

Key Points: 
  • To learn more about VEXAS and the research that the RP Foundation's support is expanding upon, check out the following articles:
    1.
  • The Relapsing Polychondritis (RP) Foundation is a 501(c)3, non-profit organization whose mission is to increase awareness and educate the broader community and medical professionals regarding relapsing polychondritis and RP-related autoimmune diseases, and support research initiatives that advance the path to a cure.
  • The Race for RP drives awareness and accelerates research support for the Relapsing Polychondritis Foundation.
  • We're working with the Relapsing Polychondritis Foundation to facilitate research and studies to help diagnose, prevent, and cure RP and its related diseases.

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

Retrieved on: 
Friday, January 14, 2022
Atopic dermatitis, Cancer, Giant cell arteritis, Juvenile idiopathic arthritis, Patient, Stroke, Lymphoma, Stomach, Skin cancer, TB, Vein, Allergy, Throat, Virus, Smoker, Psoriasis Area and Severity Index, Enzyme, Degenerative disease, Psoriatic arthritis, AbbVie, Safety, Rash, Scaly, Tears, Death, Surge arrester, Injection, NRS, Human, Disease, Skin, Tongue, Siliceous ooze, TNF, Ulcerative colitis, Time, Bacteria, Artery, Axial spondyloarthritis, Takayasu's arteritis, Infection, Crohn's disease, JAK, Extrapyramidal system, Association, HCP, Dermatitis, Risk, Tell, Rheumatoid arthritis, Shingles, Lung cancer, EASI, Sunlight, Fungus, Tuberculosis, Medical imaging, Synthetic rubber, Pharmaceutical industry, Liquor, Vaccine, Dietary supplement, Birth control, Perfume, Poultry, Copper, Frankincense, Machine tool, EU, Takayasu

RINVOQ is also approved in the EU for adults (15 mg and 30 mg) and adolescents (15 mg) with moderate to severe atopic dermatitis.

Key Points: 
  • RINVOQ is also approved in the EU for adults (15 mg and 30 mg) and adolescents (15 mg) with moderate to severe atopic dermatitis.
  • RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis.
  • It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
  • If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.

Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis

Retrieved on: 
Thursday, December 23, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Giant, Laboratory, Tocilizumab, Alkem Laboratories, CAR, Patient, Pain, Methotrexate, Joint, Fatigue, CMO, Swelling, RA, Giant cell arteritis, Fertility, Birth, Flare, Adult, Disease-modifying antirheumatic drug, Giant cell, Rheumatoid arthritis, Man, Health, Solution, Bone, MTX, CDMO, Osteoporosis, Woman, Nonsteroidal anti-inflammatory drug, CRS, Partnership, Menopause, Fine chemical, Pharmaceutical industry, Theramex, Rheumatology, Theramex, Enzene Biosciences Ltd., THERAMEX, ENZENE BIOSCIENCES LTD.

Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.

Key Points: 
  • Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.
  • Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints.
  • Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
  • For more information on Enzene Biosciences Ltd., please visit www.enzene.com
    For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com